Autolus Therapeutics (NASDAQ:AUTL) Raised to Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a neutral rating to a buy rating in a research report report published on Monday morning, MarketBeat reports. They currently have $7.60 target price on the stock, up from their prior target price of $7.00.

Several other brokerages have also recently weighed in on AUTL. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, November 11th. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Friday, November 15th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $10.15.

Autolus Therapeutics Stock Up 1.3 %

Shares of AUTL stock opened at $2.84 on Monday. The stock has a market cap of $754.37 million, a price-to-earnings ratio of -2.35 and a beta of 2.04. The business’s fifty day moving average is $3.83 and its 200 day moving average is $3.96. Autolus Therapeutics has a twelve month low of $2.69 and a twelve month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the firm earned ($0.26) earnings per share. Equities research analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AUTL. SG Americas Securities LLC bought a new position in shares of Autolus Therapeutics during the first quarter valued at $127,000. EntryPoint Capital LLC lifted its holdings in shares of Autolus Therapeutics by 113.6% during the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock valued at $137,000 after purchasing an additional 11,456 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in shares of Autolus Therapeutics by 117.7% during the first quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company’s stock valued at $21,532,000 after purchasing an additional 1,824,592 shares in the last quarter. Avoro Capital Advisors LLC bought a new position in shares of Autolus Therapeutics during the first quarter valued at $78,765,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after purchasing an additional 2,487,778 shares in the last quarter. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.